Innate Pharma discontinued its Phase 1/2 study of IPH6501, a tetraspecific antibody-based NK cell engager being evaluated in B-cell non-Hodgkin lymphoma. The company said the program was halted as part of a broader pipeline refocus and strategic prioritization. Innate had previously completed dose escalation in the trial and planned patient enrollment across the U.S., Australia, and France. In its full-year 2025 earnings materials, the company indicated data would be presented later this year, even as the clinical program itself ended. Management framed the move as part of reallocation toward higher-value assets, including a Nectin-4-targeting ADC (IPH4502) and an anti-KIR3DL2 antibody (lacuseamab) moving toward Phase 3 in Sézary syndrome. Innate also pointed to monalizumab—an anti-NKG2A antibody partnered with AstraZeneca—as a key Phase 3 catalyst. The termination underscores how quickly clinical-stage NK-engager strategies can be reshaped when trial readouts fail to secure priority within a crowded immuno-oncology landscape.